{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:54:37Z","timestamp":1790423677341,"version":"4.1.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_sjph-2018-0028_s_006_w2aab3b7b7b1b6b1aab1c18b1Aa\">\n                    <jats:title id=\"d774345e13266_w2aab3b7b7b1b6b1aab1c18b1aAa\">Introduction<\/jats:title>\n                    <jats:p>The objective was to present the results of surveillance of prion diseases in Slovenia that was established in 1996 and then to assess the interdisciplinary approach according to the algorithm of case management and reporting data to the National Register at the National Institute of Public Health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjph-2018-0028_s_007_w2aab3b7b7b1b6b1aab1c18b2Aa\">\n                    <jats:title id=\"d774345e13275_w2aab3b7b7b1b6b1aab1c18b2aAa\">Methods<\/jats:title>\n                    <jats:p>A descriptive study of Creutzfeldt-Jakob disease (CJD) recorded in the period from 1996 to 2017 was carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjph-2018-0028_s_008_w2aab3b7b7b1b6b1aab1c18b3Aa\">\n                    <jats:title id=\"d774345e13283_w2aab3b7b7b1b6b1aab1c18b3aAa\">Results<\/jats:title>\n                    <jats:p>A total of 123 cases of prion disease were notified between 1996 and 2017. Out of these, 68 were recorded and confirmed by autopsy as sporadic CJD with an average incidence rate of 1,5 cases per million population per year. In one case a gene analysis showed mutation E200K in prion protein gene, PRNP. Two cases of the Gerstman-Str\u00e4ussler Scheinker syndrome and one clinical case of fatal insomnia with new PRNP mutation, N181S, were notified. Diagnostic value of protein 14-3-3 analysis in the liquor reached 82% sensitivity and 71% specificity. 25 cases of notified clinically possible\/probable CJD were disproved after autopsy. In eleven notified possible CJD cases the autopsy had not been performed. Variant CJD has not yet been proven in Slovenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjph-2018-0028_s_009_w2aab3b7b7b1b6b1aab1c18b4Aa\">\n                    <jats:title id=\"d774345e13291_w2aab3b7b7b1b6b1aab1c18b4aAa\">Conclusion<\/jats:title>\n                    <jats:p>Incidence rates were comparable with other European countries. Completeness of reporting and proper management of CJD cases according to the algorithm of reporting, management and case confirmation would need some improvement. A well-functioning surveillance system, including timely notifications, would enable an appropriate epidemiological investigation and an effective response to public health risks, thus the awareness of prion diseases should not decline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/sjph-2018-0028","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:30:33Z","timestamp":1538544633000},"page":"227-233","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of 22 years of surveillance for prion diseases in Slovenia, 1996 to 2017"],"prefix":"10.2478","volume":"57","author":[{"given":"Nu\u0161ka","family":"\u010dak\u0161 Jager","sequence":"first","affiliation":[{"name":"National Institute of Public Health , Trubarjeva 2, 1000 Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Popovi\u0107","sequence":"additional","affiliation":[{"name":"University of Ljubljana , Medical Faculty, Institute of Pathology , Korytkova 2, 1000 Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Bla\u0161ko Marki\u010d","sequence":"additional","affiliation":[{"name":"National Institute of Public Health , Trubarjeva 2, 1000 Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Kraigher","sequence":"additional","affiliation":[{"name":"National Institute of Public Health , Trubarjeva 2, 1000 Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"2026042917465200689_j_sjph-2018-0028_ref_001_w2aab3b7b7b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"Will RG, Ironside JW, Zeidler M, Estibeiro K, Cousens SN, Smith PG, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921-5.","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_002_w2aab3b7b7b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, et al. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol. 2006;59(1):111-20.","DOI":"10.1002\/ana.20708"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_003_w2aab3b7b7b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216 (4542):136-44. 10.1126\/science.6801762","DOI":"10.1126\/science.6801762"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_004_w2aab3b7b7b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Knight R, Will RG. Prion diseases. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 1):36-42. 10.1136\/jnnp.2004.036137","DOI":"10.1136\/jnnp.2004.036137"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_005_w2aab3b7b7b1b6b1ab1b7b5Aa","unstructured":"Popovi\u0107 M. Prionske bolezni pri \u010dloveku. Med Razgl. 1997;36:181\u20139."},{"key":"2026042917465200689_j_sjph-2018-0028_ref_006_w2aab3b7b7b1b6b1ab1b7b6Aa","unstructured":"World Health Organisation. WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease, 2003. Accessed January 30th, 2018 at: http:\/\/www.who.int\/bloodproducts\/TSE-manual2003.pdf"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_007_w2aab3b7b7b1b6b1ab1b7b7Aa","unstructured":"\u010cak\u0161 Jager N. Ocena sistema epidemiolo\u0161kega spremljanja Creutzfeldt-Jakobove bolezni v Sloveniji: specialisti\u010dna naloga. Ljubljana: Univerza v Ljubljani, Medicinska fakulteta, 2011."},{"key":"2026042917465200689_j_sjph-2018-0028_ref_008_w2aab3b7b7b1b6b1ab1b7b8Aa","unstructured":"European Centre for Disease Prevention and Control (ECDC). Creutzfeldt - Jakob disease International Surveillance Network. CJD Surveillance Data 1993-2013. Accessed January 30th, 2018 at: http:\/\/www.eurocjd.ed.ac.uk\/surveillance%20data%201.html"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_009_w2aab3b7b7b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Sikorska B, Knight R, Ironside JW, Liberski PP. Creutzfeldt-Jakob disease. Adv Exp Med Biol. 2012;724:76-90. 10.1007\/978-1-4614-0653-2_6","DOI":"10.1007\/978-1-4614-0653-2_6"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_010_w2aab3b7b7b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"Collins S, McLean CA, Masters CL. Gerstmann-Str\u00e4ussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci. 2001;8(5):387-97.","DOI":"10.1054\/jocn.2001.0919"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_011_w2aab3b7b7b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull. 2003;66(1):255\u201365. org\/10.1093\/bmb\/66.1.255","DOI":"10.1093\/bmb\/66.1.255"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_012_w2aab3b7b7b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"Hsich G, Kenny K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996;335(13):924-30.","DOI":"10.1056\/NEJM199609263351303"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_013_w2aab3b7b7b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998;43(1):32-40.","DOI":"10.1002\/ana.410430109"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_014_w2aab3b7b7b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrova E, et al. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol. 2007;254:901-6.","DOI":"10.1007\/s00415-006-0472-9"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_015_w2aab3b7b7b1b6b1ab1b7c15Aa","unstructured":"Odredba o preventivnih ukrepih v zvezi s transmisivnimi spongiformnimi encefalopatijami. Uradni list RS. 2(12.1.2001):131."},{"key":"2026042917465200689_j_sjph-2018-0028_ref_016_w2aab3b7b7b1b6b1ab1b7c16Aa","unstructured":"European Centre for Disease Prevention and Control (ECDC). Facts about variant Creutzfeldt-Jakob disease. Accessed March 3rd, 2018 at: https:\/\/ecdc.europa.eu\/en\/vcjd\/facts"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_017_w2aab3b7b7b1b6b1ab1b7c17Aa","unstructured":"CDC\u2019s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD), 2010. Accessed August 30th, 2018 at: https:\/\/www.cdc.gov\/prions\/cjd\/diagnostic-criteria.html"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_018_w2aab3b7b7b1b6b1ab1b7c18Aa","unstructured":"Uprava RS za varno hrano, veterinarstvo in varstvo rastlin. Epidemiolo\u0161ko stanje pri BSE v EU in Sloveniji. Accessed January 30th, 2018 at: http:\/\/www.uvhvvr.gov.si\/si\/delovna_podrocja\/tse_transimsivne_spongiformne_encefalopatije\/epidemiolosko_stanje_pri_bse_v_eu_in_sloveniji\/"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_019_w2aab3b7b7b1b6b1ab1b7c19Aa","unstructured":"World Health Organisation (WHO). Guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies, 2006. Accessed January 30th, 2018 at: http:\/\/www.who.int\/bloodproducts\/TSEPUBLISHEDREPORT.pdf"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_020_w2aab3b7b7b1b6b1ab1b7c20Aa","unstructured":"Mitrov\u00e1 E, Belay G. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. Acta Virol. 2002;46(1):31-9."},{"key":"2026042917465200689_j_sjph-2018-0028_ref_021_w2aab3b7b7b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Slivarichov\u00e1 D, Mitrov\u00e1 E, Urs\u00ednyov\u00e1 M, Uhn\u00e1kov\u00e1 I, Koscov\u00e1 S, Ws\u00f3lov\u00e1 L. Geographic accumulation of Creutzfeldt-Jakob disease in Slovakia - environmental metal imbalance as a possible cofactor. Cent Eur J Public Health. 2011;19(3):158-64.","DOI":"10.21101\/cejph.a3667"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_022_w2aab3b7b7b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol. 2011;258(2):255-62. 10.1007\/s00415-010-5738-6","DOI":"10.1007\/s00415-010-5738-6"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_023_w2aab3b7b7b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"Kojovi\u0107 M, Glava\u010d D, O\u017eek B, Zupan A, Popovi\u0107 M. De novo P102L mutation in a patient with Gerstmann-Str\u00e4ussler-Scheinker disease. Eur J Neurol. 2011;18(12):152-3. 10.1111\/j.1468-1331.2011.03531.x","DOI":"10.1111\/j.1468-1331.2011.03531.x"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_024_w2aab3b7b7b1b6b1ab1b7c24Aa","doi-asserted-by":"crossref","unstructured":"Gubbels S, Bacci S, Laursen H, Hogenhaven H, Cowan S, Molbak K, et al. Description and analysis of 12 years of surveillance for Creutzfeldt\u2013Jakob disease in Denmark, 1997 to 2008. Euro Surveill. 2012;17(15):pii:20142. org\/10.2807\/ese.17.15.20142-en","DOI":"10.2807\/ese.17.15.20142-en"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_025_w2aab3b7b7b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"Will RG, Ironside JW, Zeidler M, Estibeiro K, Cousens SN, Smith PG, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921-5.","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_026_w2aab3b7b7b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"Hamlin C, Puoti G, Berri S, Sting E, Harris C, Cohen M, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2012;79(6):547-52. 10.1212\/WNL.0b013e318263565f","DOI":"10.1212\/WNL.0b013e318263565f"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_027_w2aab3b7b7b1b6b1ab1b7c27Aa","unstructured":"The Florey Institute of Neuroscience and Mental Health and The University of Melbourne. Australian national creutzfeldt - jakob disease registry. Accessed January 30th, 2018 at: http:\/\/ancjdr.path.unimelb.edu.au\/diagnostic-testing\/14-3-3-csf-protein-test"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_028_w2aab3b7b7b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"Loftus T, Chen D, Looby S, Chalissery A, Howley R, Heaney C, et al. CJD surveillance in the Republic of Ireland from 2005 to 2015: a suggested algorithm for referrals. Clin Neuropathol. 2017;36(4):188-94. 10.5414\/NP301016","DOI":"10.5414\/NP301016"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_029_w2aab3b7b7b1b6b1ab1b7c29Aa","doi-asserted-by":"crossref","unstructured":"Kustec T, Ke\u0161e D, Klavs I. Under-reporting of sexually transmitted infection with chlamydia trachomatis - a revision of surveillance system is required. Zdr Varst. 2016;55(3):174-8. 10.1515\/sjph-2016-0022","DOI":"10.1515\/sjph-2016-0022"},{"key":"2026042917465200689_j_sjph-2018-0028_ref_030_w2aab3b7b7b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"Budka H, Will RG. The end of the BSE saga: do we still need surveillance for human prion diseases? Swiss Med Wkly. 2015;12(145):w14212. 10.4414\/smw.2015.14212","DOI":"10.4414\/smw.2015.14212"}],"container-title":["Slovenian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/sjph\/57\/4\/article-p227.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/sjph-2018-0028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:49:08Z","timestamp":1777499348000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/sjph-2018-0028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,10,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"alternative-id":["10.2478\/sjph-2018-0028"],"URL":"https:\/\/doi.org\/10.2478\/sjph-2018-0028","relation":{},"ISSN":["1854-2476"],"issn-type":[{"value":"1854-2476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}